The Society for Immunotherapy of Cancer (SITC) Acute Leukemia Immunotherapy Guideline Expert Panel is pleased to invite public comment from April 6 – April 30, 2020 for the draft of the forthcoming, “Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of acute leukemia” manuscript.
SITC’s open public comment period allows for key stakeholders and other experts in the field – both within and outside of our membership – to critically review the guideline and provide input prior to publication. SITC is committed to maintaining full transparency in our guideline development process, in alignment with the Institute of Medicine’s standards, for the ultimate purpose of developing quality clinical practice guidelines to aid practitioners in providing the best possible care to their patients.
Instructions for participating in the open comment period are provided below. Prospective reviewers will be required to sign a non-disclosure and confidentiality agreement prior to obtaining the draft manuscript. All comments must be received by 11:59 pm PT, Thursday, April 30, 2020, to be considered.
CIG NDA ABOUT THE ACUTE LEUKEMIA EXPERT PANEL
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com